Search

Your search keyword '"Wilding, John P H"' showing total 504 results

Search Constraints

Start Over You searched for: Author "Wilding, John P H" Remove constraint Author: "Wilding, John P H"
504 results on '"Wilding, John P H"'

Search Results

5. Definition and diagnostic criteria of clinical obesity

8. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

9. The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes‐related and cancer outcomes.

12. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

13. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

14. #2496 Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial

18. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

21. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

28. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61

29. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

31. The double burden of malnutrition in individuals: Identifying key challenges and re‐thinking research focus.

34. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE)

35. Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers

40. Sibutramine

48. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes

49. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Catalog

Books, media, physical & digital resources